Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction
Cardiovascular Research
Abstract
Heart failure with preserved ejection fraction (HFpEF) continues to increase in prevalence and has limited treatment options. HFpEF is a systemic condition with a broad phenotype including diastolic dysfunction, pulmonary oedema, exercise intolerance, and left ventricular hypertrophy, collectively resulting in enhanced morbidity and mortality. The transcription factor RUNX1 has recently been identified as a mediator of pathological changes in multiple cardiac diseases; however, its role in HFpEF remained unknown.
Here, we show that inhibition of
Overall, this work enhances our understanding of RUNX1 in cardiac disease and presents a novel translational target for the treatment of HFpEF.
Contributors
Colin Berry
Author
University of Glasgow Glasgow , United Kingdom of Great Britain & Northern Ireland
Thomas Braun
Author
Gabriele G Schiattarella
Author
Mauro Giacca
Author
King's College London London , United Kingdom of Great Britain & Northern Ireland
Martin W McBride
Author
Stuart A Nicklin
Author
Ali Ali Mohamed Elbassioni
Author
Ewan R Cameron
Author
Anmar A Raheem
Author
Christopher M Loughrey
Author
University of Glasgow Glasgow , United Kingdom of Great Britain & Northern Ireland
Jian Song
Author
Eilidh A MacDonald
Author
Alexander S Johnston
Author
Cara Trivett
Author
Hong Lin
Author
Haobo Zhang
Author
Ashley Bradley
Author
Erin Higgins
Author
Cameron R Thomson
Author
Leanne Mooney
Author
Yen Chin Koay
Author
Dylan O’Toole
Author
Pawel Herzyk
Author
Colin Nixon
Author
Karen Blyth
Author
Mark Hughes
Author
Nawwar Al-Attar
Author
John F O’Sullivan
Author
Ninian N Lang
Author
University of Glasgow Glasgow , United Kingdom of Great Britain & Northern Ireland
You may be interested in
